Skip to main content
Erschienen in: BMC Infectious Diseases 1/2020

Open Access 01.12.2020 | Case report

Survival of a case of Bacillus cereus meningitis with brain abscess presenting as immune reconstitution syndrome after febrile neutropenia – a case report and literature review-

verfasst von: Yusuke Koizumi, Takafumi Okuno, Hitoshi Minamiguchi, Keiko Hodohara, Hiroshige Mikamo, Akira Andoh

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2020

Abstract

Background

Bacillus cereus sometimes causes central nervous system infection, especially in compromised hosts. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked, and mortality rate is high. We report a survived case of B. cereus meningitis/brain abscess in severe neutropenia, presenting as immune reconstitution syndrome.

Case presentation

A 54-year-old Japanese female with acute myelogenous leukemia developed B. cereus bacteremia and meningitis during consolidation chemotherapy. At the onset, she presented with mild meningism. She had marked leukocytopenia (WBC <100/μL, neutrophils 0/μL) and lumbar puncture yielded only mild pleocytosis. She was transferred to intensive care unit, and meropenem, linezolid and vancomycin was started. With intensive therapy, she recovered and once became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The antimicrobial chemotherapy was continued and finally she was cured with no complications.

Conclusions

With early diagnosis and prompt initiation and of antibiotics, the case was successfully treated without any sequelae. It is important to remember that, even under optimal antimicrobial therapy, bone marrow recovery can cause transient reaggravation of the disease. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ADA
Adenosine deaminase
AIDS
Acquired immunodeficiency syndrome
AML
Acute myeloid leukemia
CMV
Cytomegalovirus
CSF
Cerebrospinal fluid
FLAGM
Fludarabine, cytarabine, glanulocyte colony stimulating factor, and mitoxantrone combined therapy
HHV-6
Human herpes virus-6
HSV
Herpes simplex virus
LZD
Linezolid
MEPM
Meropenem
MNC
Mononuclear cells
PNC
Polymorphonuclear cells
sIL-2R
Soluble interleukin-2 receptor
VCM
Vancomycin
VZV
Varicella zoster virus
WBC
White blood cells

Background

Bacillus cereus is a Gram positive, aerobic facultative, spore-forming, rod-shaped bacterium. It is motile, catalase positive and ubiquitous, found in air, soil, water, and food [1]. Because of the ubiquitous distribution of B. cereus in food products, the bacterium is ingested in small numbers and becomes part of the transitory human intestinal flora [2]. Traditionally, the detection of Bacillus species in sterile samples has been regarded as contamination. However, the organism has the potential to cause severe infectious diseases in immunocompromised hosts [1]. Herein, we report a case of B. cereus meningitis with brain abscess, arising in the setting of neutropenia, and presenting as immune reconstitution syndrome after bone marrow recovery.

Case presentation

A 54-year-old Japanese female was diagnosed with acute myeloid leukemia (AML). Complete remission was achieved after induction chemotherapy, but 14 months later the disease relapsed. During the re-induction chemotherapy (FLAGM; fludarabine, cytarabine, granulocyte colony stimulating factor, and mitoxantrone), she experienced severe septic shock caused by Klebsiellla pneumoniae bacteremia requiring intensive care. During the consolidation therapy (high dose cytarabine), oral polymyxin B, sulfamethoxazole/trimethoprim, voriconazole, and acyclovir were administered as prophylaxis.
On day 18 of consolidation chemotherapy (day 1 of infection), she complained of fever and chills. Meropenem 3 g/day was started after blood culture sampling. On day 2, headache and nausea appeared. Diarrhea was absent, and the vital signs were as follows: blood pressure 124/67 mmHg, heart rate 86 bpm, and body temperature 39.5 °C. At this time, she was conscious and lucid. Neurologically, no abnormal focal signs, including nuchal rigidity, were noted. Laboratory tests showed marked leukocytopenia (WBC < 100/μL, neutrophils 0/μL) with slight C-reactive protein elevation (1.32 mg/dL). The blood culture detected a Gram-positive rod-shaped bacterium on day 2, and the pathogen was identified as B. cereus on day 4. The strain was resistant to penicillin and quinolones, but sensitive to carbapenems, vancomycin, and linezolid.
On day 3, disorientation, slurred speech, and confusion appeared. Slight nuchal rigidity was observed, and the neck flexion test was positive. Although meningitis was suggested, lumbar puncture was not performed because of severe thrombocytopenia (21,000/μL). Instead, linezolid (1200 mg/day), vancomycin (targeted trough of 20 mg/dL), and acyclovir (30 mg/kg/day) were administered in addition to high dose meropenem (6 g/day).
On day 5, she was transferred to the intensive care unit because of shock. At this time, lumbar puncture yielded the following results: opening pressure: 18 cmH2O; cells: 43/mm3 (mononuclear cells dominant, with no abnormal cells); glucose: 31 mg/dL; protein: 155 mg/dL; negative for HSV-DNA, VZV-DNA, CMV-DNA, HHV-6 DNA, Cryptococcus-Antigen and WT-1 (Wilms Tumor-1). Cerebrospinal fluid (CSF) culture was negative, but B. cereus PCR was positive, leading to the diagnosis as B. cereus meningitis.
With inotropic agents, deep sedation, and antimicrobials, she recovered and became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The CSF findings revealed markedly increased cells (2040 cells/mm3), and decreased glucose level (12 mg/dL). The CSF culture and PCR for B. cereus were both negative, and other diseases were excluded by the aforementioned examinations. Therefore, in concert with the increased leukocytes in peripheral blood and CSF, it was suggestive of immune reconstitution syndrome after B. cereus meningitis. The gadolinium enhanced magnetic resonance imaging (MRI) performed on day 15 had already detected meningeal thickening and several ring enhancement lesions. Glucocorticoid administration was not used to treat immune reconstitution syndrome. Meropenem, vancomycin, and linezolid were continued for 26, 40, and 45 days, respectively. They were stopped after CSF and MRI findings were confirmed to be normalized. On day 90, she was discharged to her home without any sequela, and her AML remains in remission for 5 years.

Discussion and conclusions

Central nervous system infections caused by B. cereus can be classified as three diseases: 1) postsurgical meningitis, ventriculitis or brain abscess, which can occur several days after a surgical procedure and often affects devices [3]; 2) neonatal meningitis or encephalitis occurring in premature neonates at 7 days of age (median, range 1–49 days) [4]; 3) necrotizing meningitis or hemorrhage in cases of severe neutropenia, predominantly affecting patients with leukemia (Table 1) [314].
Table 1
Three Types of Central Nervous System Bacillus cereus Infection
 
Post-Surgical Procedure/Device Infection
Neonatal Infection
Severe Neutropenia
Risk Population
Ommaya reservoir
Premature birth: 32 (27–36) weeks
WBC count <100/uL
Post intrathecal injection
Low body weight infant:1500 (830–3760) g
Induction therapy against AML
Disease Onset
Several days after procedures
7 (1–49) days after birth
Around 10 days of neutropenia
Mode of Infection
Meningitis
Meningoencephalitis
Necrotizing meningoencephalitis
Ventriculitis
 
Cerebral hemorrhage
Brain abscess
 
Subarachnoid hemorrhage
Clinical Course and Prognosis
Responds well to antimicrobial therapy
Progresses within hours
Progresses within hours
Leads to death within days
Leads to death within days
Cerebrospinal Fluid Findings
Up to 105 cells /mm3
Around 102–3 cells /mm3
Around 102 cells /mm3
Mortality rate
Low
75% (12/14 cases)
79% (11/14 cases)
References
3
3, 4
3, 6–14
While postsurgical infections typically resolve in spite of marked CSF pleocytosis, in the order of 105 cells/mm3, the latter two infection types have very poor prognoses with mortality rate greater than 75%. Notably, in many cases of these two malicious diseases, CSF cell counts are usually less than 102 cells/mm3.
Fourteen cases of neutropenia-associated B. cereus meningitis have been reported so far (Table 2). All but one case had hematological malignancies (AML: 6, acute lymphoblastic leukemia: 7, myelodysplastic syndrome: 1, aplastic anemia: 1) and all had severe neutropenia of less than 500/μL at the onset of disease. Moreover, 79% had less than 100/μL blood leukocytes, suggesting a role for severe neutropenia in the pathogenesis of this disease. The cases demonstrated mild or absent CSF pleocytosis, which is considered to be a result of both the severely immunodeficient state of the patient and the character of B. cereus infection in itself, which causes little inflammatory reaction [15].
Table 2
Clinical Characteristics of Neutropenia-Related Bacillus cereus Meningitis
Symptoms at Onset
Case
Year
Age
Underlying Diseases
WBC Count at Onset
Fever
Headache
Vomiting
Diarrhea
Abdominal Pain
Neurological Abnormalities
CNS Disease
Treatment
Outcome
Reference
1
1973
63
AML
400a
+
    
Coma
Brain abscess
GM, OXA, CBC
Dead
5
2
1981
19
AML
<100
+
     
Meningitis
GM, PCG
Dead
6
3
1988
67
MDS/AML
100a
+
+
+
   
Meningoencephalitis/SAH
GM, LM, PIPC
Dead
7
4
1989
3
ALL
20
+
    
Lethargy
Brain abscess
CP, VCM, GM, RFP
Alive
8
5
1995
26
AML
20
  
+
  
Visual disturbance
Meningoencephalitis/SAH
CAZ
Dead
9
6
1997
64
AML
300
+
 
+
+
  
Meningoencephalitis/SAH
PIPC, GM, CPZ, CTX, ABPC
Dead
10
7
1997
20
ALL
0
+
 
+
+
+
Speech disturbance, Sensory disturbance
Cerebral infarction (basal ganglia)
 
Dead
11
8
1999
13
ALL
0
+
   
+
 
Meningoencephalitis/hydrocephalus
 
Alive, Severe sequelae
11
9
1999
15
ALL
0
 
+
  
+
 
Meningoencephalitis
 
Dead
11
10
1999
30
AML
<100
+
   
+
Delirium, hyperventilation
Necrotic meningoencephalitis
CAZ, AMK
Dead
12
11
1999
43
AML
<100
+
+
+
+
+
Delirium, decerebrate rigidity
Meningoencephalitis
CAZ, AMK → VCM, GM & others
Dead
12
12
1999
14
ALL
<100
+
    
Delirium, epilepsy, coma
Meningoencephalitis
CAZ, AMK & others
Dead
12
13
2003
16
AA
90
+
+
   
Nuchal rigidity, epilepsy, consciousness disturbance
Meningoencephalitis
CAZ, IPM/CS
Dead
13
14
2005
19
HD
0
+
    
Confusion, epilepsy, hemiparesis
Meningoencephalitis
ABPC, AMK, CPFX, TEIC, CLDM
Alive
14
Our
case
54
AML
<100
+
+
+
  
disorientation, slurred speech, and confusion
Meningoencephalitis/hydrocephalus brain abscess
MEPM, LZD, VCM
Alive
 
adenotes the number of neutrophils
Abbreviations: AA Aplastic anemia, ABPC Ampicillin, ALL Acute lymphoblastic leukemia, AMK Amikacin, AML Acute myelogenous leukemia, CAZ ceftazidime, CBC, carbenicillin, CLDM Clindamycin, CNS Central nervous system, CP Chloramphenicol, CPFX Ciprofloxacin, CPZ Cefoperazone, CTX Cefotaxime, GM Gentamicin, HD Hodgkin disease, IPM/CS Imipenem/cilastatin, LM Lincomycin, LZD Linezolid, MDS Myelodysplastic syndrome, MEPM Meropenem, OXA Oxacillin, PCG Penicillin G, PIPC Piperacillin, RFP Rifampin, VCM Vancomycin
Our case shared common features with previous reports such as severe neutropenia at the onset of meningitis and the complication of brain abscesses. While those are typical findings of neutropenia associated B. cereus meningitis, there are two particular features of this report. First, with an early diagnosis and administration of a contemporary antimicrobial regimen, we were able to cure the disease without any complications. The regimen contained antibiotics with good penetrance, including linezolid, high dose meropenem, and a well-controlled dose of vancomycin that achieved a serum trough level of 20 μg/mL. This well-structured regimen was started immediately after the onset of meningitis, though the physical findings were subtle in the early phase, and CSF findings at day 5 showed only a moderate level of pleocytosis. This early diagnosis is crucial for the rapid initiation of intensive antimicrobial therapy.
Second, we were able to closely track the CSF and MRI findings with the recovery of hematopoiesis. The patient’s meningitis symptoms were improving until day 19, when neutrophils rapidly increased. With the recovery of neutrophil count, a dramatic worsening of fever, consciousness and meningism was demonstrated. This could be considered as a type of immune reconstitution syndrome, though the term originally denoted the recovery of cellular immunity from AIDS or other immunosuppressive states. As shown in Fig. 1, we serially observed parameters of cellular immunity as well as neutrophil count. Interestingly, the severity of meningitis symptoms clearly synchronized with the blood neutrophil count, and the correlation is even more dramatic for CSF cells, CSF soluble interleukin-2 receptor (sIL-2R), and CSF adenosine deaminase (ADA). On day 19, the vast majority of CSF cells were polymorphonuclear cells (neutrophils). Later, CSF, sIL-2R and ADA increased, indicating that a typical inflammation cascade was ongoing. As differential diagnosis, other infections or an intracranial recurrence of AML were considered, but negative culture, cytology and clinical course were indicative of B. cereus meningitis. Therefore, we continued the antibiotics and the symptoms gradually improved.
In conclusion, we experienced a case of B. cereus meningitis with brain abscess during severe neutropenia from which the patient survived. With serial measurement of inflammatory / immunological markers, our report described the phenomenon resembling immune reconstitution syndrome, and we also proved that contemporary antimicrobial regimens can cure this severe disease. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked. Because immediate diagnosis is crucial for survival, clinicians should be able to carefully recognize the symptoms and interpret the clinical data in order to rapidly initiate intensive treatment. Furthermore, it is important to remember that bone marrow recovery can cause transient reaggravation of the disease, even under optimal antimicrobial therapy. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.

Acknowledgements

None to declare.
Informed consent was obtained from the patient after verbal and written information provision. All the procedures have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
We have confirmed that the participant gave written consent for her personal or clinical details along with any identifying images to be published in this study.

Competing interests

The authors declare that they have no competing interets.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23:382–98.CrossRef Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23:382–98.CrossRef
2.
Zurück zum Zitat Turnbull PCB, Kramer JM. Intestinal carriage of Bacillus cereus: fecal isolation studies in three population groups. J Hyg (Lond). 1985;95:629–38.CrossRef Turnbull PCB, Kramer JM. Intestinal carriage of Bacillus cereus: fecal isolation studies in three population groups. J Hyg (Lond). 1985;95:629–38.CrossRef
3.
Zurück zum Zitat Stevens MP, Elam K, Bearman G. Meningitis due to Bacillus cereus: a case report and review of the literature. Can J Infect Dis Med Microbiol. 2012;23:e16–9.CrossRef Stevens MP, Elam K, Bearman G. Meningitis due to Bacillus cereus: a case report and review of the literature. Can J Infect Dis Med Microbiol. 2012;23:e16–9.CrossRef
4.
Zurück zum Zitat Manickam N, Knorr A, Muldrew KL. Neonatal meningoencephalitis caused by Bacillus cereus. Pediatr Infect Dis J. 2008;27:843–6.CrossRef Manickam N, Knorr A, Muldrew KL. Neonatal meningoencephalitis caused by Bacillus cereus. Pediatr Infect Dis J. 2008;27:843–6.CrossRef
5.
Zurück zum Zitat Ihde DC, Armstrong D. Clinical spectrum of infection due to Bacillus species. Am J Med. 1973;55:839–45.CrossRef Ihde DC, Armstrong D. Clinical spectrum of infection due to Bacillus species. Am J Med. 1973;55:839–45.CrossRef
6.
Zurück zum Zitat Colpin GG, Guiot HF, Simonis RF, Zwaan FE. Bacillus cereus meningitis in a patient under gnotobiotic care. Lancet. 1981;8248:694–5.CrossRef Colpin GG, Guiot HF, Simonis RF, Zwaan FE. Bacillus cereus meningitis in a patient under gnotobiotic care. Lancet. 1981;8248:694–5.CrossRef
7.
Zurück zum Zitat Funada H, Uotani C, Machi T, Matsuda T, Nonomura A. Bacillus cereus bacteremia in an adult with acute leukemia. Jpn J Clin Oncol. 1988;18:69–74.CrossRef Funada H, Uotani C, Machi T, Matsuda T, Nonomura A. Bacillus cereus bacteremia in an adult with acute leukemia. Jpn J Clin Oncol. 1988;18:69–74.CrossRef
8.
Zurück zum Zitat Jenson HB, Levy SR, Duncan C, Mcintosh S. Treatment of multiple brain abscesses caused by Bacillus cereus. Pediatr Infect Dis J. 1989;8:795–8.CrossRef Jenson HB, Levy SR, Duncan C, Mcintosh S. Treatment of multiple brain abscesses caused by Bacillus cereus. Pediatr Infect Dis J. 1989;8:795–8.CrossRef
9.
Zurück zum Zitat Marley EF, Saini NK, Venkatraman C, Orenstein JM. Fatal Bacillus cereus meningoencephalitis in an adult with acute myelogenous leukemia. South Med J. 1995;88:969–72.CrossRef Marley EF, Saini NK, Venkatraman C, Orenstein JM. Fatal Bacillus cereus meningoencephalitis in an adult with acute myelogenous leukemia. South Med J. 1995;88:969–72.CrossRef
10.
Zurück zum Zitat Motoi N, Ishida T, Nakano I, Akiyama N, Mitani K, Hirai H, Yazaki Y, Machinami R. Necrotizing Bacillus cereus infection of the meninges without inflammatory reaction in a patient with acute myelogenous leukemia: a case report. Acta Neuropathol. 1997;93:301–5.CrossRef Motoi N, Ishida T, Nakano I, Akiyama N, Mitani K, Hirai H, Yazaki Y, Machinami R. Necrotizing Bacillus cereus infection of the meninges without inflammatory reaction in a patient with acute myelogenous leukemia: a case report. Acta Neuropathol. 1997;93:301–5.CrossRef
11.
Zurück zum Zitat Gaur AH, Patrick CC, McCullers JA, Flynn PM, Pearson TA, Razzouk BI, Thompson SJ, Shenep JL. Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis. 2001;32:1456–62.CrossRef Gaur AH, Patrick CC, McCullers JA, Flynn PM, Pearson TA, Razzouk BI, Thompson SJ, Shenep JL. Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis. 2001;32:1456–62.CrossRef
12.
Zurück zum Zitat Musa MO, Al Douri M, Khan S, Shafi T, Al Humaidh A, Al Rasheed AM. Fulminant septicaemic syndrome of Bacillus cereus: three case reports. J Inf Secur. 1999;39:154–6. Musa MO, Al Douri M, Khan S, Shafi T, Al Humaidh A, Al Rasheed AM. Fulminant septicaemic syndrome of Bacillus cereus: three case reports. J Inf Secur. 1999;39:154–6.
13.
Zurück zum Zitat de Almeida SM, Teive HA, Brandi I, Nabhan SK, Werneck LC, Bittencourt MA, Medeiros CR, Pasquini R, de Mello HH. Fatal Bacillus cereus meningitis without inflammatory reaction in cerebral spinal fluid after bone marrow transplantation. Transplantation. 2003;76:1533–4.CrossRef de Almeida SM, Teive HA, Brandi I, Nabhan SK, Werneck LC, Bittencourt MA, Medeiros CR, Pasquini R, de Mello HH. Fatal Bacillus cereus meningitis without inflammatory reaction in cerebral spinal fluid after bone marrow transplantation. Transplantation. 2003;76:1533–4.CrossRef
14.
Zurück zum Zitat Haase R, Sauer H, Dagwadordsch U, Foell J, Lieser U. Successful treatment of Bacillus cereus meningitis following allogenic stem cell transplantation. Pediatr Transplant. 2005;9:338–41.CrossRef Haase R, Sauer H, Dagwadordsch U, Foell J, Lieser U. Successful treatment of Bacillus cereus meningitis following allogenic stem cell transplantation. Pediatr Transplant. 2005;9:338–41.CrossRef
15.
Zurück zum Zitat Burdon KL, Davis JS, Wende RD. Experimental infection of mice with Bacillus cereus: studies of pathogenesis and pathologic changes. J Infect Dis. 1967;117:307–16.CrossRef Burdon KL, Davis JS, Wende RD. Experimental infection of mice with Bacillus cereus: studies of pathogenesis and pathologic changes. J Infect Dis. 1967;117:307–16.CrossRef
Metadaten
Titel
Survival of a case of Bacillus cereus meningitis with brain abscess presenting as immune reconstitution syndrome after febrile neutropenia – a case report and literature review-
verfasst von
Yusuke Koizumi
Takafumi Okuno
Hitoshi Minamiguchi
Keiko Hodohara
Hiroshige Mikamo
Akira Andoh
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2020
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4753-1

Weitere Artikel der Ausgabe 1/2020

BMC Infectious Diseases 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.